Literature DB >> 7197584

Comparison of the iv and ip routes of administration of cisplatin in dogs.

R G Pretorius, E S Petrilli, C K Kean, L C Ford, J D Hoeschele, L D Lagasse.   

Abstract

Cisplatin at a dose of 3 mg/kg was administered to dogs either iv or ip. Cisplatin concentrations in serum, urine, and tissues were measured with a radioisotope tracer method employing 195mPt cisplatin. Systemic toxicity was monitored by serial BUN, creatinine, and wbc and platelet counts. The mode of administration did not affect systemic toxicity since the changes in renal and bone marrow functions were identical in the two groups. Serum cisplatin levels following iv administration peaked at 13.5 micrograms/ml at 5 minutes and were biphasic with rapid initial decline and a prolonged elimination phase. In contrast, levels following ip administration increased rapidly to 1.5 micrograms/ml at 4 hours and then decreased with the iv levels. The amount of drug recovered in the urine was similar regardless of method of administration, with approximately 50% of the injected dose excreted by Day 4. The drug levels within the tissues on Days 4 and 8 were similar, with the exception of the tissues lining the peritoneal cavity. On Day 4 the tissues lining the peritoneal cavity had 2.5-8 times higher levels of drug after ip administration, and this difference was statistically significant (P less than 0.01). Local toxic effects encountered with ip administration consisted of bloody ascites on Day 4 (four of none dogs) and filmy adhesions on Day 8 (one of four dogs). It is concluded that ip cisplatin chemotherapy may increase the therapeutic index for small tumors which are confined to the peritoneal cavity.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7197584

Source DB:  PubMed          Journal:  Cancer Treat Rep        ISSN: 0361-5960


  15 in total

Review 1.  [Hyperthermic intraperitoneal chemotherapy].

Authors:  H Leebmann; P Piso
Journal:  Chirurg       Date:  2019-07       Impact factor: 0.955

Review 2.  Pharmacokinetics and pharmacodynamics of intraperitoneal cancer chemotherapeutics.

Authors:  Csilla Hasovits; Stephen Clarke
Journal:  Clin Pharmacokinet       Date:  2012-04-01       Impact factor: 6.447

3.  Ovarian carcinomatosis in a dog managed with surgery and intraperitoneal, systemic, and intrapleural chemotherapy utilizing indwelling pleural access ports.

Authors:  Matthew P Best; Angela E Frimberger
Journal:  Can Vet J       Date:  2017-05       Impact factor: 1.008

Review 4.  Antitumor activity of platinum complexes.

Authors:  J Drobník
Journal:  Cancer Chemother Pharmacol       Date:  1983       Impact factor: 3.333

Review 5.  Cisplatinum: a review, with special reference to cellular and molecular interactions.

Authors:  C L Litterst
Journal:  Agents Actions       Date:  1984-12

6.  "Two-route chemotherapy" using cis-diamminedichloroplatinum(II) and its antidote, sodium thiosulfate, combined with angiotensin II is effective against peritoneally disseminated cancer in rats.

Authors:  H Kobayashi; K Hasuda; K Aoki; T Kuroiwa; S Taniguchi; T Baba
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

7.  Physiological model for the pharmacokinetics of cis-dichlorodiammineplatinum (II) (DDP) in the tumored rat.

Authors:  F F Farris; F G King; R L Dedrick; C L Litterst
Journal:  J Pharmacokinet Biopharm       Date:  1985-02

8.  Preoperative intraperitoneal chemotherapy for gastric cancer, with special reference to delayed peritoneal complications.

Authors:  W Adachi; S Koike; M Rafique; S Kajikawa; G Kaneko; T Kuroda; F Iida; K Ishii
Journal:  Surg Today       Date:  1995       Impact factor: 2.549

9.  Physiological pharmacokinetic modeling of cis-dichlorodiammineplatinum(II) (DDP) in several species.

Authors:  F G King; R L Dedrick; F F Farris
Journal:  J Pharmacokinet Biopharm       Date:  1986-04

10.  Comparative distribution and excretion of carboplatin and cisplatin in mice.

Authors:  Z H Siddik; M Jones; F E Boxall; K R Harrap
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.